Something to Think About
The five-hour session led the rheumatologists on a journey from epigenetics in physiology to epigenetics in pathophysiology to a description of a drug with an epigenetic target poised to enter a phase 2 trial. The journey was exhausting, and many members of the audience were also battling jet lag, but they left the session with the air of visitors who had been exposed to a newly discovered wing of the castle. There was excitement and the sense the session gave them a lot to think about.
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
